Shorter Durations of Anti-HER2 Therapy for Patients with Early-Stage, HER2-Positive Breast Cancer: The Physician Perspective

Despite evidence from clinical trials showing the efficacy of shorter durations of therapy, most HER2-positive early breast cancer (EBC) patients receive a year of anti-HER2 therapy. A survey of Canadian oncologists was conducted online, with electronic data collection, and the analysis is reported...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Michelle Bradbury, Marie-France Savard, Lisa Vandermeer, Lucas Clemons, Gregory Pond, John Hilton, Mark Clemons, Sharon McGee
Formato:	Artigo
Idioma:	Inglês
Publicado em:	MDPI AG 2023-12-01
coleção:	Current Oncology
Assuntos:	breast cancer HER2 trastuzumab
Acesso em linha:	https://www.mdpi.com/1718-7729/30/12/763
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!